These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38971103)

  • 1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors.
    Liu J; Zhu J
    Int Immunopharmacol; 2024 Sep; 138():112609. PubMed ID: 38971103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody based therapeutics: Strengths and challenges.
    Thakur A; Huang M; Lum LG
    Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
    Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
    Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
    Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
    Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
    Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.
    Moore DC; Digiantonio N; Oxencis CJ; Taucher KD
    Am J Health Syst Pharm; 2024 Jul; 81(14):574-582. PubMed ID: 38394329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin.
    Liu JJ; Pan ZD; Yue YL; Wang SS; Chen J; Jiang H; Zhang BH; Wu MY; Yuan YS; Bian YL; Yin HY; Wang L; Li JY; Gilly J; Xie YQ; Zhu JW
    Acta Pharmacol Sin; 2024 Oct; 45(10):2186-2198. PubMed ID: 38858494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
    Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
    Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
    Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
    Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
    Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
    Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
    Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances.
    Yu L; Wang J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):941-956. PubMed ID: 30798356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
    Stoltzfus CR; Sivakumar R; Kunz L; Olin Pope BE; Menietti E; Speziale D; Adelfio R; Bacac M; Colombetti S; Perro M; Gerner MY
    Front Immunol; 2021; 12():726492. PubMed ID: 34421928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of adaptive immune effector therapies in solid tumors.
    Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
    Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
    Borogovac A; Siddiqi T
    Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.